Featured Research

from universities, journals, and other organizations

On-site pathology improves the inadequacy rate of ultrasound-guided thyroid biopsies

Date:
May 5, 2010
Source:
American College of Radiology / American Roentgen Ray Society
Summary:
Having a pathologist on-site during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies that are often performed due to an inadequate sample from the first procedure, according to a new study.

Having a pathologist on-site during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies that are often performed due to an inadequate sample from the first procedure, according to a study to be presented at the American Roentgen Ray Society 2010 Annual Meeting in San Diego, CA.

"Requests for ultrasound-guided biopsies for the diagnosis of thyroid nodules have increased rapidly in recent years, putting a strain on radiology departments everywhere," said Wui K. Chong, MD, lead author of the study. Unfortunately, there are a number of inadequate biopsies (where the pathologist deems there is an insufficient amount of information to make a diagnosis) that ultimately must be repeated.

"Repeat biopsy is unpleasant and inconvenient for the patient and is obviously wasteful. Having a pathologist on-site to review the specimen can cut down on the number of patients returning for repeat biopsy, thus making more efficient use of resources," said Chong.

The study, performed at the University of North Carolina in Chapel Hill, NC, compared 200 biopsies that were performed with a pathologist on-site and 200 that were not. "We found that all other factors being equal, 13.5 percent of biopsies performed without a pathologist on-site were inadequate, compared to only 5 percent that were performed with a pathologist on-site," said Chong.

"As a result of this study, we recommend that radiologists performing large numbers of thyroid biopsies use on-site pathology as it may reduce the need for repeat biopsy by up to 60 percent," he said.


Story Source:

The above story is based on materials provided by American College of Radiology / American Roentgen Ray Society. Note: Materials may be edited for content and length.


Cite This Page:

American College of Radiology / American Roentgen Ray Society. "On-site pathology improves the inadequacy rate of ultrasound-guided thyroid biopsies." ScienceDaily. ScienceDaily, 5 May 2010. <www.sciencedaily.com/releases/2010/05/100505091628.htm>.
American College of Radiology / American Roentgen Ray Society. (2010, May 5). On-site pathology improves the inadequacy rate of ultrasound-guided thyroid biopsies. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/05/100505091628.htm
American College of Radiology / American Roentgen Ray Society. "On-site pathology improves the inadequacy rate of ultrasound-guided thyroid biopsies." ScienceDaily. www.sciencedaily.com/releases/2010/05/100505091628.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins